Beyond the successful breakout of the stochastic AND the crossover of the MACD, MindMed had a positive earnings report that beat expectations.
All of the pieces are in play for this pattern to play out against expectations - and the break to the upside seems imminent.
You don't have to (and legally shouldn't) listen to me, but I'm sitting happily on my...
*This is not financial advice, so trade at your own risks*
*My team digs deep and finds stocks that are expected to perform well based off multiple confluences*
*Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management*
My team has been following clinical-stage biotech company $LCTX for the past...
Medical stock that's too thinly traded got mixed review on clinical trial results on Tivozanib, which showed efficacy, just not to level expected and testing new low for 2018 at 2.03 and below full fibonacci retracement of 2.10 as prior low. NASDAQ:AVEO
Technicals:
Nordic Nanovector retraced from recent high to fill gaps down to support at NOK 48, which triggered a strong reversal pattern.
Investors will be keen to follow if the stock establishes a trading range above 53 NOK which would represent a breakout from the recent downtrend, and even more if the stock could possibly break free from the almost two year...
AIT Therapeutics Inc. is a clinical-stage biopharmaceutical company using nitric oxide (NO) to treat serious lung infections and pulmonary hypertension. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections that are not effectively addressed with current standards of care. AIT Therapeutics is advancing its...
$CTRV to present at the 2017 Marcum MicroCap Conference being held June 15-16. 2017, at the Grand Hyatt New York in New York City .60s on this stock has always been a massive support level since 2014. Go back far enough and you can see where the stock hits .60 and then moves back to multi-dollars. This CEO doesn't do R/S's he is an old school OG who knows how to...
"team appointed to conduct clinical trials of its insomnia products using Blake’s proprietary Zleepax™ formula"
This looks like a typical reversal play after a huge run up. The news from March 2 introduces the team behind the clinical study. There is a huge market for this. Could be a nice reversal play here.
www.otcmarkets.com
Outstanding Shares 31,597,572 a/o...
